StreetInsider.com News Articles

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 19:06:00 -0400

JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of the Senior Director’s employment with the Company, as a material inducement to the employee’s acceptance of employment, and was approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The award was granted

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 19:06:00 -0400

The award was granted

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 19:06:00 -0400

The award was granted

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 19:06:00 -0400

The award was granted

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26929154.html

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26929154.html

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: GREAT POINT PARTNERS LLC

Fri, 14 Aug 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20260814/26925867.html

Form SCHEDULE 13G/A SCYNEXIS INC Filed by: GREAT POINT PARTNERS LLC

Fri, 14 Aug 2026 09:33:00 -0400

si-local-file:///var/storage/secattach/20260814/26925867.html

SCYNEXIS (SCYX) PT Raised to $33 at Guggenheim

Thu, 13 Aug 2026 06:47:48 -0400

(Updated - August 13, 2026 6:47 AM EDT)

Guggenheim analyst Vamil Divan raised the price target on SCYNEXIS (NASDAQ: SCYX) to $33.00 (from $24.00) while maintaining a Buy rating.

The analyst commented: "We are increasing our price target on SCYX shares to $33 (from $24) and reiterating our Buy rating following multiple conversations with nephrologists that leave us more optimistic on both the mechanistic rationale and commercial opportunity for SCY-770 (formerly PXL-770) in autosomal dominant polycystic kidney disease (ADPKD). The transaction for SCY-770 with Poxel fundamentally reoriented SCYX from an antifungal-focused company to a rare renal disease company, with ADPKD the lead

SCYNEXIS (SCYX) PT Raised to $33 at Guggenheim

Thu, 13 Aug 2026 06:47:48 -0400

(Updated - August 13, 2026 6:47 AM EDT)

Guggenheim analyst Vamil Divan raised the price target on SCYNEXIS (NASDAQ: SCYX) to $33.00 (from $24.00) while maintaining a Buy rating.

Form SCHEDULE 13G SCYNEXIS INC Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26911271.html

Form SCHEDULE 13G SCYNEXIS INC Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26911271.html

Scynexis (SCYX) Tops Q2 EPS by 114c

Mon, 10 Aug 2026 17:21:17 -0400

Scynexis (NASDAQ: SCYX) reported Q2 EPS of $0.63, $1.14 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $80.33 thousand.

For earnings history and earnings-related data on Scynexis (SCYX) click here.

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update